Market research
APC.V Advanced Proteome Therapeutics Corporation
V CAD Healthcare
Latest close
Latest stored close unavailable
Test a moving-average rule with historical data.
Market facts
- Market cap
- 823K
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 1.37
Profile
Instrument facts
- Exchange
- V
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Biotechnology & Medical Research
- ISIN
- CA0076282098
- Market cap
- 823K
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 1.37
About
About Advanced Proteome Therapeutics Corporation
Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., operates as a biotechnology company in the United States. The company develops and commercializes a platform for the chemical modification of protein therapeutics. Its platform is dedicated to applications in the field of antibody drug conjugates, as well as focused on protein conjugates and immunomodulation. The company is headquartered in Burnaby, Canada.
Research context
Advanced Proteome Therapeutics Corporation appears in PyInvesting’s TSX Venture Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Biotechnology & Medical Research
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the APC.V discussion.
5 years, 6 months ago
Advanced Proteome Therapeutics Corporation is currently in a long term uptrend where the price is trading 92.3% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Advanced Proteome Therapeutics Corporation's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 200.6% to $-342K since the same quarter in the previous year.
Finally, its free cash flow fell by 107.1% to $-231K since the same quarter in the previous year.
Based on the above factors, Advanced Proteome Therapeutics Corporation gets an overall score of 2/5.